Adriana Bastidas, Javier de la Serna, Mohamed El Idrissi, Lidia Oostvogels, Philippe Quittet, Javier López-Jiménez, Filiz Vural, David Pohlreich, Tsila Zuckerman, Nicolas C Issa, Gianluca Gaidano, Je-Jung Lee, Sunil Abhyankar, Carlos Solano, Jaime Perez de Oteyza, Michael J Satlin, Stefan Schwartz, Magda Campins, Alberto Rocci, Carlos Vallejo Llamas, Dong-Gun Lee, Sen Mui Tan, Anna M Johnston, Andrew Grigg, Michael J Boeckh, Laura Campora, Marta Lopez-Fauqued, Thomas C Heineman, Edward A Stadtmauer, Keith M Sullivan
IMPORTANCE: Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. OBJECTIVE: To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. DESIGN, SETTING, AND PARTICIPANTS: Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT...
July 9, 2019: JAMA